Brimonidine tartrate

Cat. No.: 0225LY-1204

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Brimonidine Tartrate is a quinoxaline-derived adrenergic alpha-2 receptor agonist (EC50: 0.45 nM) utilized clinically to regulate intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Synonym: AGN190342 tartrate; 304 tartrate; AGN190342 (tartrate); 70359-46-5; Alphagan; Brimonidine tartarate; Brominide tartrate; Brimonidine L-Tartrate; Qoliana; Lumify; Bromoxidine tartrate; AGN 190342LF; AGN 190342-LF; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate; 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine;(2R,3R)-2,3-dihydroxybutanedioic acid; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate (1:1); (2R,3R)-2,3-dihydroxybutanedioic acid; 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1); 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1)

CAS No.: 70359-46-5

Compound CID: 54405

Formula: C₁₅H₁₆BrN₅O₆

Formula Weight: 442.22

Specification

Targets&IC50: α2A-adrenoceptor: 0.45 nM(EC50)

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Brimonidine tartrate can be used in ophthalmology research to examine the reduction of intraocular pressure through alpha-2 adrenergic receptor activation.